PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34010002-0	2021	Toll-like Receptor-4 (TLR4) Agonist-Based Intranasal Nanovaccine Delivery System for Inducing Systemic and Mucosal Immunity.	nanovaccine	53-64	toll like receptor 4	Homo sapiens	0-20	
34010002-0	2021	Toll-like Receptor-4 (TLR4) Agonist-Based Intranasal Nanovaccine Delivery System for Inducing Systemic and Mucosal Immunity.	nanovaccine	53-64	toll like receptor 4	Homo sapiens	22-26	
33547233-3	2021	Here, by screening a group of cationic lipid-like materials, we developed a minimalist nanovaccine with C1 lipid nanoparticle (LNP) that could efficiently deliver mRNA in antigen presenting cells with simultaneous Toll-like receptor 4 (TLR4) activation and induced robust T cell activation.	nanovaccine	87-98	toll like receptor 4	Homo sapiens	214-234	
33547233-3	2021	Here, by screening a group of cationic lipid-like materials, we developed a minimalist nanovaccine with C1 lipid nanoparticle (LNP) that could efficiently deliver mRNA in antigen presenting cells with simultaneous Toll-like receptor 4 (TLR4) activation and induced robust T cell activation.	nanovaccine	87-98	toll like receptor 4	Homo sapiens	236-240	
30569516-8	2019	This nanovaccine platform in combination with checkpoint inhibition of PD-L1 represents a promising approach to improve the cancer immunotherapy of TLR4 agonists.	nanovaccine	5-16	toll like receptor 4	Homo sapiens	148-152